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Prediction softwarein silico epitope prediction, as well as in vivo and in vitro approaches.We inoculated
BALB/c (H2d)micewith 17DD yellow fever vaccine to investigate the correlations between approaches used for
epitope discovery: ELISPOT assays, binding assays, and prediction software. Our results showed a good
agreement between ELISPOT and binding assays, which seemed to correlate with the protein immunogenicity.
PREDBALB/c prediction software partially agreed with the ELISPOT and binding assay results, but presented low
speciﬁcity. The use of prediction software to exclude peptides containing no epitopes, followed by high
throughput screening of the remaining peptides by ELISPOT, and the use of MHC-biding assays to characterize
the MHC restrictions demonstrated to be an efﬁcient strategy. The results allowed the characterization of
2 MHC class I and 17 class II epitopes in the envelope protein of the YF virus in BALB/c (H2d) mice.
© 2008 Elsevier Inc. All rights reserved.IntroductionIn the last decade,many groups have devoted attention to the study
of the immunomes of a variety of viruses with the goal of obtaining
new insights that could support the development and improvement of
vaccines, viral diagnosis, and further our understanding of the immune
system (Peters et al., 2005; Sette and Fikes, 2003; Sette et al., 2005).
Immunome, as deﬁned by Sette and co-workers (Sette et al., 2005),
is the detailed map of immune reactions of a given host interacting
with a foreign antigen, and immunomics can be deﬁned as the study of
immunomes. The identiﬁcation of the T and B cell immune response
targets allows the design of antigenic formulations focused on selected
epitopes, for instance, promoting more robust responses against
subdominant epitopes contained in conserved sequences that do not
easily toleratemutants escape. In addition, it makes it possible to avoidorbent spot assay; IC50, 50%
cells; SFC, spot-forming cells.
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l rights reserved.the presence of inhibitory epitopes (Disis et al., 1996), allows the
combination of many epitopes from different proteins or organisms
(Sercarz et al.,1993) and the avoidance of immunopathogenic epitopes.
Hence, immunomics offers a powerful approach to the rational design
of vaccines (Sette and Fikes, 2003).
In addition to prediction software approaches (Moutaftsi et al.,
2006; Yewdell, 2006), ELISPOT (Anthony and Lehmann, 2003), ﬂow
cytometry (Hoffmeister et al., 2003), binding assays (Sidney et al.,
1998), and human leukocyte antigen (HLA)-transgenic mice (Sette and
Fikes, 2003) are the most frequently used tools for epitope discovery.
Among those, ELISPOToffersmany positive advantageswith regards to
characterizing the immune response (e.g. looking at different cyto-
kines and/or subpopulations of cells), by offering some degree of
automation, broader options for readouts (e.g., IFN-γ, IL-2, and IL-4),
the screening of large number of peptides, and rapid results (Anthony
and Lehmann, 2003). Although the length of the peptides used in
ELISPOTassays can vary from 9 to 20 amino acids, libraries of 15 amino
acids (15mers) with an offset of 11 amino acids seem to represent the
best compromise between epitope coverage of a protein sequence and
the ability to detect CD4+ and CD8+ responses (Kiecker et al., 2004).
Several factors are known to modulate the repertoire of T cells
responses, such as the protein's three-dimensional structure, its
processing, presentation, MHC–peptide afﬁnity, T cell receptor (TCR)
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antigen formulations are prepared and presented to the host
organism. Therefore, a high-quality characterization of an immunome
must include the testing of multiple immunization protocols using
antigens inoculated via different routes and doses, with the immune
responses tested at different points in time (Assarsson et al., 2007).
Since it is nearly impossible to test all the potential antigen formu-
lations and screen all the peptides that might induce responses, it
is important to include in the immunome study reductionist
approaches that are subjected to fewer variables. One of the
most commonly used approaches is the biochemical MHC–peptide
binding assay. The direct in vitro evaluation of peptides that can bind
MHC molecules, as determined by competition assays, is likely to
identify a larger pool of possible epitopes that would not actually
bind in vivo, due to various processing and chaperone mechanisms,
which are part of the immunodominant shaping mechanisms
(Yewdell, 2006).
The use of prediction software has also become a very important
tool for epitope discovery. Such software is intended to save time and
money by allowing investigators to pre-screen the sequence of a
protein or a list of peptides for the presence of possible targets for the
immune response. Different mathematical models are used in the
search for peptides that can bind to MHCmolecules with high afﬁnity.
These models can be as simple as matrices of frequencies of individual
amino acids in a given position in a peptide sequence or as complex as
artiﬁcial neural network models; this topic has been reviewed else-
where (Braga-Neto and Marques, 2006).
The YF virus is an interesting target for immunome studies, with a
number of useful relevant tools available that facilitate these studies,
such as an effective human live-attenuated virus vaccine and
accepted animal challenge models. YF is a deadly arthropod-borne
virus of the ﬂavivirus family that is currently circulating in tropical
and subtropical areas of the world (Figueiredo, 2007; Monath, 2001;
World Health Organization, 2003). The 17D, 17D-213, and 17DD, YF
strains used for human vaccination are products of multiple passages
of the virulent parental Asibi virus (Galler et al., 1997). The molecular
basis of the attenuation has been identiﬁed, and all the vaccine
strains have been shown to differ from the wild-type virus in a few
amino acids (dos Santos et al., 1995; Galler et al., 1997; Jennings et al.,
1993; Post et al., 1992). The strain 17D has been successfully used
worldwide for more than 65 years. It has an extraordinary record of
safety, conferring long-lasting immunity for up to 35 years in asmany
as 99% of those vaccinated (Poland et al., 1981; World Health
Organization, 2003).
The humoral neutralizing response against the YF envelope
protein, one of its three structural proteins, has been recognized as
one of the major mechanisms to account for the protection elicited by
the vaccine (Monath, 1986; Monath and Barrett, 2003), although data
increasingly point to an important role for the cellular arm of the
immune response in protection against infection (Co et al., 2002). A
few MHC-restricted T cell epitopes have been described in mice
(Regner et al., 2001; van der Most et al., 2002) and humans (Co et al.,
2002), but their contribution to the immunity induced by the vaccine
is still not understood. It was recently reported that the YF 17D vaccine
can infect dendritic cells (DC) (Barba-Spaeth et al., 2005) and is able to
activate innate immune responses through toll-like receptors (TLR)
(Querec et al., 2006).
We used the 17DD YF virus as a surrogate model for our
immunomics studies of the YF virus structural proteins. Murine T
cell responses were evaluated ex vivo through ELISPOT IFN-γ assays
with overlapping peptide libraries encompassing the entire length of
each of the three YF structural proteins (envelope, capsid, and
membrane). These results were then compared to a computational T
cell epitope prediction method, PREDBALB/c, which is based on binding
matrix models for each of the ﬁve MHC alleles present in the BALB/c
mouse, and to binding assay results for all ﬁve H2-D alleles. All theepitopes described in this study can be found in the Immune Epitope
Database —IEDB (http://www.immuneepitope.org/home.do) (Peters
et al., 2005).
Results
Evaluation of the kinetics and dose–response of BALB/c mice to the
immunization with the human 17DD YF vaccine
In order to deﬁne a suitable immunization protocol for immunome
studies using the human 17DD YF virus, groups of BALB/c mice were
immunized three times, at 2-week intervals, with either a high
(105 pfu) or low dose (104 pfu) of the 17DD YF vaccine and were
assayed ex vivo by IFN-γ ELISPOT assay using 16mer peptides from the
YF envelope protein, (Supplemental Table 1). A detectable T cell
response was observed in both mice groups with the high and low
doses 14 days after the ﬁrst immunization (Supplemental Fig. 1A and
B). The second immunization led to a more focused T cell response to
fewer 16mer peptides (Supplemental Figs. 1C and D) and the third
immunization did not change the pattern observed after the second
immunization (Supplemental Fig. 1E and F). The evaluation of the
humoral response after each immunization (data not shown)
indicated that after two immunizations with either the high or low
dose of the vaccine, both groups reached similar levels of IgG anti-YF
(ELISA with virus lysate), and that the third immunization did not
enhance the antibody levels. The results of these experiments
(Supplemental Fig. 1) indicated that an immunization protocol with
two low dosed of the 17DD YF vaccine given three weeks apart would
be enough to induce an optimal T cell response, and hence, such
protocol was applied in the subsequent experiments, except when
indicated.
Analysis of CD4+ and CD8+ responses to the YF envelope protein peptides
Seven days after the second immunization, the splenocytes of the
mice receiving two low doses (104 pfu) of the human 17DD YF
vaccine 3 weeks apart were assayed by ELISPOT with 15mer
peptides (15×11) of the 17DD YF envelope protein (Supplemental
Table 2). A high number of IFN-γ SFC was observed against several
peptides of the envelope protein (Fig. 1A) and the main positive
responses were directed to the same regions in the YF envelope
protein previously observed with the 16mer peptides (16×10)
(Supplemental Fig. 1).
We further characterized the cellular response using splenocytes
depleted of CD4+ or CD8+ lymphocytes. The depletion approach
consistently yielded N95% of depletion, as judged by ﬂow cytometry
(data not shown). CD4-depleted cells, which were used to address
the CD8+ response, showed signiﬁcant numbers of IFN-γ SFC in
response to three of the peptides (Fig. 1B), while the CD8-depleted
cells, which correspond to the CD4+ response, showed signiﬁcant
numbers of IFN-γ SFC in response to 17 peptides (Fig. 1C). These
results were compatible with the ﬁndings obtained with total
splenocytes (Fig. 1A) and characterized the immunogenic peptides
either as MHC class I or class II antigens. As an additional control,
experiments were performed with puriﬁed CD4+ or CD8+ T cells
incubated with splenocytes from naive mice as APC, and the ELISPOT
results were comparable to those obtained with depleted popula-
tions (data not shown). Two of the peptides (E57–71 and E61–75)
promoted IFN-γ secretion from both CD4+ and CD8+ T cells,
suggesting that these 15mers contain epitope motifs for class I and
class II molecules, whereas the remaining immunogenic peptides
induced either CD4+ or CD8+ responses.
The T cell repertoire of the immunized mice was also investigated
at 4.5 and 9 months after the initial immunization protocols, with or
without a recall boost right before the experiments (Supplemental
Fig. 2). In these long-term memory experiments, we observed the
Fig.1. Response of total splenocytes and CD4+ and CD8+ Tcells to the peptides of the YF envelope protein. BALB/cmicewere immunized on day 0 and boosted on day 21with 104 pfu of
the human 17DD YF vaccine, and the splenocytes were tested in IFN-γ ELISPOT assays 7–10 days after the boost. The peptides used for in vitro stimulation were 15mers, overlapping
by 11 amino acids and comprising the length of the envelope protein (10 μg/mL). (A) splenocytes; (B) CD4-depleted splenocytes; (C) CD8-depleted splenocytes. Figures represent the
average of two to four experiments performed with a pool of three to ﬁve mice each. Bars indicate the mean±SD.
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the second 17DDYF immunization. The peptides corresponding to the
CD8+ response appeared to be the most dominant immune responses
present at all times tested.
Characterization of the CD8+ responses to the YF envelope protein
peptides
The CD8+ T cells preferentially recognize peptides of 8–10 amino
acids present in the groove of MHC class I molecules. Therefore, the
pattern of CD8+ response to 15mers does not deﬁne the minimal
sequences that are being recognized. To address this issue, we
examined how CD8+ T cells from mice immunized with our standard
17DDYF virus protocol react in vitrowith all the possible 9mers that are
present within each of the three CD8-immunogenic 15mer peptides
(Table 1; Supplemental Table 5). For the ﬁrst two CD8-immunogenic
15mers, E57–71 and E61–75, we considered the amino acid sequence
between position E57 and E75 of the envelope protein, which results in
11 peptides of 9 amino acids overlapped by 8 amino acids (9×8). For
the third CD8-immunogenic 15mer (E329–343), the sequence between
E329 and E343 was considered, i.e., 7 peptides of 9 amino acids, over-
lapped by 8 amino acids.
The results of the IFN-γ ELISPOT assays using 9mer peptides to
stimulate the in vitro responses are presented in Figs. 2A and B.
Within the ﬁrst set of 9mers (E57 to E75), the 9mer peptide E60–68induced the highest number of IFN-γ SFC, while in the second set
of 9mers (E329–343), the peptide E330–338 stimulated the highest
number of IFN-γ SFC. However, in both 9mer sets, other 9mer
peptides were also able to stimulate a signiﬁcant number of IFN-
gamma SFC. In order to determine how the concentration of
peptide used in the ELISPOT assay could inﬂuence the results, we
conducted a second round of experiments using decreasing in vitro
concentrations of peptide (10, 1, and 0.1 μg/mL) (Figs. 2C and D). In
these experiments, peptide E60–68 induced the highest number of
IFN-γ SFC at all concentrations tested, showing a high in vitro
stimulatory activity for CD8+ T cells of mice immunized with the
17DD YF virus (Fig. 2C). Peptide E64–73 showed an intermediate
stimulatory level, while all the other peptides in the same set
induced measurable IFN-γ secretion only at the highest concentra-
tion of 10 μg/mL.
In the second set of 9mer peptides, E332–340 showed the strongest
CD8+ stimulatory responsewith the peptide concentration of 10 μg/mL
(Fig. 2D). Contrarily to what was expected, peptide E330–338, which
consistently induced the highest number of IFN-γ SFC at 10 μg/mL in
the ELISPOT assays, showed only an intermediate stimulatory curve.
Peptide E335–343 also showed an intermediate stimulatory activity,
while the remaining peptides induced only a very low response, and
only at 10 μg/mL.
Taken together, the results pointed out that the 9mer E332–340 was
signiﬁcantly less potent than E330–338 to activate a large number of
Table 1
Results of ELISPOT, binding assay and PREDBALB/c prediction for the 9mer peptides from the CD8-positive sequences of the yellow fever envelope protein
9mer position
(Yellow Fever
Envelope) Sequence
# IFN-γ SFC
(CD4-depleted
splenocytes/106) (2)
Binding assay (IC50 in nmol)
(PREDBALB/c score)
E57 to E75 RKVCYNAVLTHVKINDKCP(1) Dd (3) Kd (3) Ld (3)
57–65 RKVCYNAVL(4) 1 N70,000(5) N70,000 39,442
(7.98) (5.72) (4.70)
58–66 KVCYNAVLT 93 N70,000 N70,000 N70,000
(2.32) (1.84) (0.90)
59–67 VCYNAVLTH 265 N70,000 211⁎ 55,368
(7.98) (1.60) (4.62)
60–68 CYNAVLTHV 403 N70,000 1.0⁎ N70,000
(6.48) (8.66⁎⁎) (5.18)
61–69 YNAVLTHVK 143 N70,000 93⁎ N70,000
(3.46) (1.92) (0.90)
62–70 NAVLTHVKI 7 N70,000 1542 N70,000
(8.42⁎⁎) (5.56) (0.30)
63–71 AVLTHVKIN 60 N70,000 54,670 20,708
(4.10) (1.10) (0.88)
64–72 VLTHVKIND 60 N70,000 N70,000 N70,000
(2.94) (5.22) (2.22)
65–73 LTHVKINDK 51 N70,000 N70,000 N70,000
(4.02) (1.60) (1.50)
66–74 THVKINDKC 1 N70,000 N70,000 N70,000
(0.80) (2.26) (0.40)
67–75 HVKINDKCP 6 N70,000 N70,000 48,666
(1.64) (0.58) (2.5)
E329 to E343 PCRIPVIVADDLTAA(6)
329–337 PCRIPVIVA 158 N70,000 N70,000 N70,000
(4.78) (0.50) (0.44)
330–338 CRIPVIVAD 371 N70,000 915 54,239
(2.36) (2.40) (2.12)
331–339 RIPVIVADD 140 N70,000 N70,000 N70,000
(8.50⁎⁎) (4.18) (1.42)
332–340 IPVIVADDL 63 N70,000 33,005 56⁎
(6.72) (6.00) (7.50)
333–341 PVIVADDLT 26 N70,000 N70,000 3719
(3.40) (1.80) (0.00)
334–342 VIVADDLTA 86 N70,000 N70,000 19,242
(2.70) (3.10) (1.50)
335–343 IVADDLTAA 46 N70,000 N70,000 38,032
(3.46) (1.96) (0.90)
(1) Sequence of 19 amino acids that correspond to 15mer peptides E57–71 and E61–75 that were positive for CD8 response by ELISPOT (Fig. 2B); (2) peptides were considered ELISPOT
positives when N20 SFC/106 cells; (3) molecules of H2d class I; (4) sequence of each 9mer in relation to the sequence from where it is found in the envelope protein; (5) IC50 for the
binding assay for class I molecule (nmol); (6) sequence of 15 amino acids from the 15mer peptide E329–343 (Fig. 2B); ⁎values of IC50 below the cutoff of 500 nmol, suggestive of a
possible binder peptide; ⁎⁎ score above 8 from PREDBALB/c software prediction.
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could activate relatively higher number of IFN-γ SFC at lower peptide
concentrations (Fig. 2D). It suggests that, in animals immunized
with the 17DD YF vaccine, peptides E332–340 and E330–338 may be
stimulating different populations of CD8+ T cells. The CD8+ T cell
population activated by E332–340 seems to be smaller in number, but
with a higher avidity for its MHC–peptide complex then the CD8+ T
cell population stimulated by E330–338. In these conditions, it is
possible that two partially overlapping class I epitopes exist. However,
we cannot discard the hypothesis that the in vivo processing and
availability of these two epitope are different after the immunization
with the 17DD YF vaccine, leading to the priming and generation of
different numbers of CD8+ T cell clones with distinct MHC–peptide
afﬁnities.
In order to determine whether antigen peptide processing of the
17DDYF virus is affecting the availability of the peptides and therefore
inﬂuencing the pattern of the in vitro recognition and activation of the
cells, mice were immunized with each individual 9mer present in the
two sets of immunogenic peptide sequences that produced the
highest CD8+ responses, namely E57 to E71 and E329 to E343. Additional
control groups were immunized with a mixture of all 9mers pooled
together and with the 15mers fromwhich the 9mers were generated.
The cells of each group were then tested in ELISPOT assays withdecreasing concentrations of all peptides, as means of evaluating the
avidity of the CD8 response (Fig. 3).
Among the seven 9mers in the ﬁrst set, peptides E57–65, E62–70 and
E63–71 failed to induce any response after individual immunization
(Figs. 3A, F, G). Other four peptides, E58–66, E59–67, E60–68, and E61–69
were able to induce IFN-γ SFC (Fig. 3B–E). Peptide E60–68, as previously
observed, showed a very high avidity in the ELISPOT assays, inducing
high numbers of IFN-γ SFC at all concentrations of the peptide used
for the in vitro stimulation (Fig. 3D). The immunization with peptides
that were closely related to peptide E60–68 was also able to induce cells
that preferably responded to peptide E60–68, suggesting that a sharing
of binding motifs may be the mechanism behind the indirect
stimulations. As expected, direct immunization with the 15mer E57–
71 also induced a strong response to peptide E60–68, further supporting
the concept that this sequence contains the class I motif needed for
the CD8 response (Fig. 3I).
The immunization with the 9mers within the E329 to E343 region
produced results distinct of those observed after immunization
with 17DD YF virus (Fig. 4). The peptides E329–337, E331–339, E333–341,
and E334–342wereunable to elicit a signiﬁcant response, as evidencedby
the very low numbers or total lack of IFN-γ SFC after in vitro stimulation
with the respective peptides (Figs. 4A, C, E, F). Peptide E330–338,
which induced a very strong stimulation after immunization with the
Fig. 2. CD8 responses to 9mer peptides of the YF envelope protein. Splenocytes of BALB/cmice immunized twicewith the human 17DDYF vaccine were used for IFN-γ ELISPOT assays.
The percentage of responses for each peptide was calculated according to the formula: number of spots at 1 μg/mL (or 0.1 μg/mL)×100/number of spots at 10 μg/mL. (A) Number of
IFN-γ SFC for peptides of 9 amino acids within the E57–75 sequence of the YF envelope protein; (B) number of IFN-γ SFC for the 9mers within the E329–343 sequence of the YF envelope
protein; (C) IFN-γ ELISPOT evaluation of the afﬁnity of CD8 responses to decreasing in vitro concentrations of 9mers within the E57–75 sequence of the YF envelope protein; (D) IFN-γ
ELISPOTevaluation of the afﬁnity of CD8 responses to decreasing in vitro concentration of 9mers within the E329–343 sequence of the YF envelope protein. Panels A and B represent the
average of three experiments with a pool of two to three mice. Panels C and D illustrate one representative experiment out of three.
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peptide emulsiﬁed in adjuvant (Fig. 4B). In contrast, the immunization
with peptides E332–340 and E335–342 activated relatively higher numbers
of IFN-γ SFC (Figs. 4D and G) then the immunization with E330–338,
to the in vitro stimulationwith the respective peptides. Of note, peptides
E332–340 and E335–343 were able to stimulate the secretion of IFN-γ in a
cross-reactive fashion, in that both peptides could cross-stimulate the
IFN-γ secretion in mice individually immunized with either one of
them. Moreover, E332–340 and E335–343 were preferably recognized by
splenocytes from mice immunized with the pool of 9mers, as well
as those immunized with 15mer E329–343 (Figs. 4H, I). The numbers of
IFN-γ SFC obtained with E332–340 were very high, evenwith the lowest
in vitro concentration of 0.1 μg/mL (Figs. 4D, G–I), paralleling the avidity
curve previously obtained (Fig. 2D). These results further support the
possibility that E330–338 and E332–340 are different epitopes and suggest
that either processing of the peptides and/or post-translational
modiﬁcations of the 17DD YF virus interfere with presentation of
these epitopes.
Biochemical characterization of the class I epitopes of the YF envelope
protein by binding assay
Subsequently, the afﬁnity between the MHC class I molecules and
the immunogenic 9mer peptides were evaluated in binding assays, by
directly measuring the afﬁnity of each peptide to all three MHC class I
molecules present in the BALB/c mouse strain (Table 1). All eighteen
possible 9mers between residues E57 and E75 and between E329 and
E340 were assayed to determine their binding afﬁnities to H2-Dd, -Kd,
and Ld molecules.The binding assay results (Table 1) demonstrated that peptide
E60–68 has the highest afﬁnity of all the peptides tested, being able to
inhibit the binding of the competitor peptide to the H2-Kd molecule
at 1 nmol, a result that was consistent with the ﬁndings from the
ELISPOT assays. In addition, adjoining peptides E59–67 and E61–69,
positioned right before and after E60–68 and consequently sharing
eight amino acids, also exhibited some degree of afﬁnity for H2-Kd
(211 and 93 nmol, respectively); these results could explain why
those peptides were also able to stimulate IFN-γ secretion, even
without a high avidity, as observed in the ELISPOT assays (Fig. 2C),
and also suggest that 8–10mer peptides covering that region can be
immunogenic.
Among the 9mers present in the sequence E329 to E343, peptide
E332–340 exhibited the highest afﬁnity (IC50=56 nmol) for the H2-Ld
molecule, while all the other peptides had an IC50 higher than the
minimum cutoff value of 500 nmol to be considered a good class I
binder (Table 1). Curiously, neither peptide E330–338 nor E335–340 per-
formed well in terms of binding to any of the class I alleles, although
they were able to stimulate IFN-γ SFC in the ELISPOT assays with
splenocytes of mice immunized with 17DD virus or peptides, even at
low peptide concentrations (Figs. 2 and 4).
Characterization of the CD4+ peptides in mice immunized with the 17DD
YF vaccine
The seventeen 15mer immunogenic peptides that had been
considered positive in ELISPOT assays with splenocytes and with
CD8-depleted cells (Fig. 1C) of mice immunized with the 17DD YF
vaccine were further characterized. The peptides were tested in
Fig. 3. Cellular responses to immunization with 9mers from the sequence E57 to E71 of the YF envelope protein. BALB/c mice were immunized s.c. once with 50 μg/mL of individual 9mers, a pool of 9mers, or a 15mer, emulsiﬁed v/v in adjuvant
(TiterMax®). The splenocytes were used in IFN-γ ELISPOTassays 15–30 days after the immunization. The cells were stimulated in vitrowith individual peptides in decreasing concentrations. The boxon the x-axis indicates the peptide(s) used in
the immunization: Mice were immunized with (A) peptide E57–65; (B) peptide E58–66; (C) peptide E59–67; (D) peptide E60–68; (E) peptide E61–69; (F) peptide E62–70; (G) peptide E63–71; (H) a pool of 9mers; (I) 15mer peptide E57–71. Each plot
represents one of three experiments using a single mouse; bars represent the average±SD of the ELISPOT duplicate.
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Fig. 4. Cellular responses to immunization with peptides from E329–343 of the YF envelope protein. BALB/c mice were immunized s.c. once with 50 μg/mL of individual 9mers, a pool of 9mers, or a 15mer, emulsiﬁed v/v in adjuvant (TiterMax®).
Splenocytes were used in IFN-γ ELISPOT assays 15–30 days after the immunization. The cells were stimulated in vitro with individual peptides in decreasing concentrations. The box on the x-axis indicates the peptide(s) used in the
immunization: Mice were immunized with (A) peptide E329–337; (B) peptide E330–338; (C) peptide E331–339; (D) peptide E332–340; (E) peptide E333–341; (F) peptide E334–342; (G) peptide E335–343; (H) a pool of 9mers; (I) 15mer peptide E329–343. Each
plot represents one of three experiments using a single mouse; bars represent the average±SD of the ELISPOT duplicate. 111
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Fig. 3). Peptides E57–71, E61–75, E129–143, and E133–147 were able to induce
a high CD4+ response evenwhen stimulated in vitro 1 or 0.1 μg/mL; the
other peptides showedonly an intermediate or low level of stimulatory
activity.
Next, the afﬁnity of the CD4-immunogenic peptides to theH2d class
II molecules I-Ad and I-Ed was tested by binding assays (Table 2).
Peptides E129–143, E133–147, E233–247, E237–251, E325–439, and E465–479
showed afﬁnities lower than 1000 nmol (cutoff for MHC class II
binders). Two of them, peptides E129–14 and E133–147, were among theTable 2
Results of ELISPOT, binding assay and PREDBALB/c prediction for the CD4-positiv
ELISPOT 15mer peptides of the yellow fever envelope protein
A list of 94 peptides selected by PREDBALB/c with score above 9 was compared to the CD4
ELISPOT results. The 9mers selected by the prediction software are shown below each
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yones that also showed immunogenicity in ELISPOT assays at low
peptide concentrations. All other immunogenic peptides tested
showed a low afﬁnity in the binding assays (IC50N1000 nmol). It is
important to note that peptides E129–143 and E133–147, and E233–247 and
E237–251 are adjacent and therefore share 11 amino acids, which may
explainwhy both peptides in the two pairs showed similar IC50 values,
as well as why they induced high numbers of IFN-γ SFC after the
immunization with the 17DD YF vaccine. All six peptides below the
cutoff showed a high afﬁnity for I-Ad suggesting that these peptides are
being presented by theMHC class II I-Ad molecule. In addition, peptide
E233–247, also showed a high afﬁnity for I-Ed (Table 2) suggesting that
this peptide may be presented by both, I-Ad and I-Ed molecules.
Comparison between the ELISPOT results and PREDBALB/c prediction
software results for the YF envelope protein
Prediction software is generally used before in vitro testing in order
to identify possible MHC binder peptides in a protein or to test the
likelihood of a speciﬁc peptide inducing an immune response when
tested bymethods such as ELISPOT. Here, we used PREDBALB/c after our
ELISPOT and binding experiments in order to evaluate how well the
software would perform in anticipating the positive peptides, as well
as in avoiding testing of peptides that did not induce a positive
response. Thus, we evaluated the performance of PREDBALB/c to predict
possible binders to all the H2d alleles (Dd, Kd, Ld, I-Ad, and I-Ed). We
subjected the list of 120 15mer peptides from the envelope protein of
the 17DD YF virus (Supplemental Table 2) to PREDBALB/c prediction
analysis for class I and class II alleles, independently. It is important to
note that in our simulation, the use of either the list of 15mers or the
whole sequence of the envelope protein rendered comparable results,
possibly due to the high degree of coverage offered by the scheme of
15 amino acids overlapping 11 (Kiecker et al., 2004).
The software analyzed all possible 9mers within each peptide,
ranking each peptide according to the highest score found (scores
range from 1 to 10) (Zhang et al., 2005). For each one of the alleles, an
output result list with 120 scored peptides was generated. Once these
lists of peptides were sorted from high to low score, we compared
each list to the ELISPOT results (Fig. 1), attempting to visualize the
PREDBALB/c score threshold that eliminated the largest number of
negative peptides while keeping the positive peptides.
In the case of the class I prediction results for the 120 15mer
peptides from the envelope protein, a threshold score of 9 eliminated
all positive peptides, while a threshold of 8 included all three positive
15mers observed in the CD8 response (E57–71, E61–75, and E329–434;
Fig. 1B). After removing all the repeated peptides in each allele's list,
the PREDBALB/c indicated 91 peptides as highly probable binders
regardless of the class I allele. If the 91 peptides had been assayed
instead of 120 15mer peptides, this approach would have reduced by
24% the number of peptides to test by ELISPOT.
We further evaluated the discrimination of the possible binders
found in the PREDBALB/c results by comparing the results produced by
the software to all 9mer peptides that were eventually used to
characterize the CD8+ response by ELISPOT (Fig. 2), as shown inTable 1.
The software correctly predicted E60–68 (score 8.66 for H2-Kd), which
was positive by ELISPOT and also presented a high afﬁnity for H2-Kd
in binding assays. However, it failed by positively predicting peptide
E62–70 (score 8.42 for H2-Dd), which was not positive by ELISPOT or by
binding assay. Peptide E331–339 was predicted (score 8.50 for H2-Dd)
although it induced only a secondary ELISPOT response and showedno
afﬁnity in the binding assay. On the otherhand, peptide E330–338,which
induced a very strong ELISPOT response, was not predicted by the
software (Table 1).
The overall comparison of the ELISPOT results, binding assay re-
sults, and PREDBALB/c predictions can be seen in the Fig. 6. The diagram
illustrates the differences in immunogenicity as deﬁned by ELISPOT
responses, epitope prediction, and binding assays.
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some of them contained known anchor residues, which in the case of
the MHC class I molecules, were consistent with the MHC restrictions
found in the binding assays (Supplemental Table 4). However, the
MHC class II restriction of 15mer peptides was less evident since
anchor motifs for both I-Ad and I-Ed could be found in a same peptide
(Supplemental Table 7).
Analysis of the T cell response to the YF virus capsid and membrane
protein peptides
As described before, BALB/c mice were immunized twice with the
17DD YF vaccine, 3 weeks apart. The ELISPOT experiments were
performed with a set of 15mers, overlapping by 11 amino acids, which
comprise the entire length of the capsid (Supplemental Table 3) and
membrane proteins (Supplemental Table 4).
Figs. 5A and B show the proﬁles of the responses of CD4- and CD8-
depleted cells to the capsid peptides in IFN-γ ELISPOT assays. Peptide
C33–47 corresponded to the CD8+ response while three other peptides,
C61–75, C77–91, and C81–95, were positive for the CD4+ response. Among
those, C77–91 and C81–95 showed a high afﬁnity for theMHC class II I-Ad
molecule in binding assays (Table 3). In addition, other peptides
showed a high afﬁnity for MHC class II I-Ad and I-Ed alleles, as seen on
Table 3. Unfortunately, the binding properties of the 9mers within the
CD8 positive region C33 to C47 were not evaluated because these
peptides were not available.
The analysis of the capsid 15mer peptides using the PREDBALB/c
software yielded 18 peptides above the PREDBALB/c software threshold
of 8 (18/28) with probable class I binding motifs and 27 peptides
above the threshold of 9 (27/28) with probable class II binding motifs
(data not shown). Although the prediction algorithm produced a high
number of false-positives for the capsid protein, all the peptides thatFig. 5. Cellular responses of BALB/c mice to the peptides of the YF capsid and membrane pro
by ELISPOT assays for the (A) number of IFN-γ SFC for CD8-depleted splenocytes and (B) nu
11 amino acids from the YF capsid protein (10 μg/mL). (C) number of IFN-γ SFC in CD8-deplet
overlapping by 11 amino acids from the YF membrane protein (10 μg/mL). Results represenwere deﬁned as immunogenic by ELISPOT were found in the software
prediction list. (Fig. 6B).
The number of IFN-γ SFC for the 15mers from the YF virus
membrane protein were overall relatively very low in the BALB/c
mice immunized with the 17DD YF vaccine as compared to the
responses elicited against the envelope protein, and no peptide was
considered positive by ELISPOT (Figs. 5C and D). However, the
binding analysis of the membrane 15mer peptides for class II mole-
cules indicated that several peptides bound to I-Ad (results on Table
4). The PREDBALB/c software predicted 10 peptides for class I epitopes
above a threshold of 8 (10/16) and 12 peptides for class II epitopes
with a threshold above 9 (data not shown). Among the 12 peptides
predicted to have class II epitopes, 6 showed high afﬁnity in the
binding assays (Table 4; Fig. 6C).
Discussion
Others studies have previously analyzed the immune response to
the YF vaccine using different immunization protocols with higher
doses of the YF virus (van der Most et al., 2002). In those
investigations, only a limited number of epitopes were reported;
thus, it appears that the immunization protocol or infection model
may be an important variable determining the epitope repertoire, and
protocol variations can lead to differences in the results obtained.
However, it is also possible that differences in the sensitivity of the
readout assays used (e.g. ﬂow cytometry versus ELISPOT) as well as
the strain of the virus and mouse strain used, could account for the
observed results.
The immunogenic CD8 peptides of the YF envelope protein
elicited higher numbers of IFN-γ SFC than the immunogenic CD4
peptides did. This pattern was also observed in the memory
experiments, in which the peptides inducing responses in CD8+ Ttein. BALB/c mice were immunized s.c. with the human 17DD YF vaccine and assessed
mber of IFN-γ SFC for CD4-depleted splenocytes, using 15mer peptides, overlapping by
ed splenocytes and (D) number of IFN-γ SFC in CD4-depleted splenocytes, using 15mers
t the mean±SD from three experiments.
Table 3
Results of class II binding assay for the 15mer peptides from the yellow fever capsid
protein
(1) Position of each 15mer peptide in the capsid protein (C) of the yellow fever virus; (2)
molecules of H2d class II (3) IC50 result for the binding assay for H2d class II molecules
(nmol); ⁎values of IC50 below the cutoff of 1000 nmol, suggestive of a possible binder
peptide; Shading — peptides positive for CD4 response by ELISPOT (Fig. 6A).
l
l II binding a say for the 15mer peptides from the yellow fever capsid
(1) Position of each 15mer peptide in the capsid protein (C) of the yellow fever virus;
(2) molecules of H2d class II (3) IC50 result for the binding assay for H2d class II
olecules (nmol); ⁎values of IC50 below the cutoff of 1000 nmol, suggestive of a
possible binder peptide; Shading — peptides positive for CD4 response by ELISPOT
(Fig. 6A).
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immunodominant peptides were able to stimulate both CD8+ and
CD4+ T cells to secrete IFN-γ (E57–71 and E61–75) in 17DD YF vaccine
immunized mice, likely boosting the immune response by allowing a
closer level of collaboration between the cytotoxic and helper arms of
the immune response.
The sequence E60–68 was shown to promote the highest number
of IFN-γ SFC in 17DD YF vaccine immunized mice. However, other
related 9mer adjacent peptides were also immunogenic. It has
previously been demonstrated that peptides of 8 to 10 amino acids
can bind H2b class I alleles (H2-Kb and -Db) (Moutaftsi et al., 2006),
and likely this is also true for H2d class I alleles. The ELISPOT assays
using decreasing in vitro concentrations of peptides may provide a
measure of the avidity between the MHC–peptide complex and the
TCR (Hesse et al., 2001). At the same time, this approach can
indirectly reﬂect the afﬁnity of the TCR–peptide interaction (Hesse et
al., 2001), which can lead to distinct cell responses, as well as to
different degrees of activation (Wilson et al., 2004). Our results
showed that 9mer E60–68 not only induced the highest number of
IFN-γ SFC but also had the highest dose–response curve, indicating a
very high avidity for the MHC–peptide[E60-68]:TCR complex in 17DD
YF vaccine immunized mice. Peptide E64–72 showed an intermediate
level of avidity, while all the other 9mers had a very low avidity,
supporting the conclusion that the results can be dependent on the
in vitro peptide concentration used in the ELISPOT assays. However,
a biological role for the responses that were observed only at high in
vitro concentrations cannot be disregarded. The additional binding
data showed that peptide E60–68 indeed bound the class I allele H2-Kd
with very high afﬁnity and that the adjoining peptides, E59–67 andE61–69, also had a high afﬁnity for H2-Kd, despite the fact that they
showed a low dose–response curve in the ELISPOT assays.
Peptide E330–338, which induced the high number of IFN-γ SFC in
mice immunized with the 17DD YF vaccine, showed only an inter-
mediate dose–response curve with decreasing peptide concentrations
in the ELISPOT, suggesting that theMHC–peptide[E330-338]:TCR avidity
was low. This peptide also failed to induce a strong immune response
when used directly in immunization protocols, and its recognitionwas
inhibited when the immunization was performed in the presence of
other peptides covering the adjacent amino acid sequences (Fig. 5H).
Moreover, E330–338 also had a low afﬁnity in the binding assay. On the
other hand, peptide E332–340, which activated about half of the number
of IFN-γ SFC induced by E330–338, showed a very high ELISPOT avidity
curve in 17DD YF vaccine immunized mice and had very high afﬁnity
for H2-Ld, as determined in the binding assays. Furthermore, peptide
E332–340 was able to induce a very strong and dominant immune
response when used directly in the immunization protocol with
adjuvant (Fig. 4D). These results point out the beneﬁts of performing
ELISPOT assays with different concentrations of peptides, after a ﬁrst
round of screening. This approach can identify peptides that only
induce responses at high concentration, aswell as evaluate the peptide
avidity.
The identiﬁcation of a class I epitope in E329–E343 of the YF virus
envelope protein is partially supported by previous work of Rothman
and colleagues, whomapped the H2d class I epitope 331SPCKIPFEI339 in
the envelope protein of the dengue-2 virus, another member of the
ﬂavivirus family (Rothman et al., 1996). Although YF and the dengue
virus do not share complete amino acid identity in the 331–339 region
of the envelope protein, the presence of a class I epitope at the same
position in the envelope protein in both viruses suggests a selective
evolution of the immune system to target the same region.
Peptide E335–343, which induced a low number of IFN-γ SFC and
presented an intermediate ELISPOT avidity curve after immunization
with 17DD YF vaccine (Fig. 2D), was able to induce a vigorous
immune response when used to immunize mice directly (Fig. 4G).
Interestingly, in the direct immunization with 9mer peptides plus
adjuvant, E332–340 and E335–343 induced IFN-γ SFC in a cross-reactive
fashion (Figs. 4D and G), even though E335–343 apparently did not
seem to be a good MHC binder in the in vitro binding assay. Other
studies have demonstrated that the binding afﬁnity in biochemical
assays does not always correlate with cytotoxic potential and that,
for some epitopes, a lower afﬁnity favors a higher level of
cytotoxicity by CD8+ T lymphocytes (Ochoa-Garay et al., 1997). In
this sense, the identiﬁcation of low afﬁnity epitopes can be useful in
vaccine development.
Recently, two groups described protective MHC class I restricted-
epitopes in the envelope of the West Nile ﬂavivirus in the context of
H2b alleles (C57Bl/6 mouse), (Brien et al., 2007; Purtha et al., 2007).
There is no data supporting the protective role of the cytotoxic
response against YF and it would be interesting to test if theMHC class
I epitopes described here can confer some degree of protection to the
YF infection. A better characterization of the cellular response against
the YF could lead to new vaccine formulations and new parameters of
protection besides the humoral response used today.
It is possible that the broader repertoire of the CD4-positive
peptides observed here is partially responsible for the strong humoral
response observed against the YF envelope protein (Monath, 1986;
Monath and Barrett, 2003), which can provide help to B cells that
recognize neutralizing epitopes. In fact, Zhao and colleagues have
demonstrated that class II epitopes of the SARS coronavirus nucleo-
protein are able to support the production of neutralizing antibodies
against the virus (Zhao et al., 2007). It is possible that other cytokines
such as IL-4 and IL-5 are also secreted in response to other peptides of
the envelope protein. Furthermore, the CD4+ T cells activated by
peptides of the envelope protein can help support CD8+ Tcell cytotoxic
clones that are important to the defence against the virus as well as
Fig. 6. Venn diagram representation of results obtained from ELISPOT assay binding assay, and PREDBALB/c prediction. (A) ELISPOT results with 120 15mer peptides from the envelope
of the YF virus with CD8-depleted splenocytes; PREDBALB/c was used to analyze the 120 15mer peptides from the envelope for the presence of class II (I-Ad and I-Ed) binders; ⁎only the
seventeen peptides positive by ELISPOT were analyzed by binding assays for class II molecules, and those showing an IC50b1000 nM were considered possible binders. (B) ELISPOT
results for the 3 out of 28 15mer peptides from the capsid of the YF virus that were considered positive with CD8-depleted splenocytes; PREDBALB/c was used to analyze the 28 15mer
peptides from the capsid for the presence of class II (I-Ad and I-Ed) binders; all 28 15mers from the capsid were tested in binding assays for class II molecules, and those showing an
IC50b1000 nMwere considered possible binders. (C) ELISPOT results with the 16 15mer peptides from the membrane of the YF virus with CD8-depleted splenocytes; PREDBALB/c was
used to analyze the 16 15mer peptides from the membrane for the presence of class II (I-Ad and I-Ed) binders; all 16 were tested in binding assays for class II molecules, and those
showing an IC50b1000 nMwere considered possible binders. (D) ELISPOT results for the 18 9mers from the envelope of the YF virus tested with CD4-depleted splenocytes; PREDBALB/c
was used to analyze the 18 9mer for the presence of class II (I-Ad and I-Ed) binders; all 9mers were tested in binding assays for class I molecules, and those showing an IC50b500 nM
were considered possible binders. The intersection represents the number of peptides that were positive in two or three of the approaches.
Table 4
Results of class II binding assay for the 15mer peptides from the yellow fever membrane
protein
Position(1) Sequence Binding Assay (IC50 in nmol)
I-Ad(2) I-Ed(2)
M1–15 AIDLPTHENHGLKTR N45,000 36,639
M5–19 PTHENHGLKTRQEKW 13,183 N45,000
M9–23 NHGLKTRQEKWMTGR 40,852 N45,000
M13–27 KTRQEKWMTGRMGER 1903 N45,000
M17–31 EKWMTGRMGERQLQK 20,419 20,683
M21–35 TGRMGERQLQKIERW 42,531 N45,000
M25–39 GERQLQKIERWFVRN N45,000 13,242
M29–43 LQKIERWFVRNPFFA 593⁎ 1559
M33–47 ERWFVRNPFFAVTAL 7.3⁎ 2278
M37–51 VRNPFFAVTALTIAY 40⁎ 1917
M41–55 FFAVTALTIAYLVGS 6213 N45,000
M45–59 TALTIAYLVGSNMTQ 102⁎ N45,000
M49–63 IAYLVGSNMTQRVVI 383⁎ 29,666
M53–67 VGSNMTQRVVIALLV 30⁎ 32,305
M57–71 MTQRVVIALLVLAVG 6484 N45,000
M61–75 VVIALLVLAVGPAYS 380⁎ N45,000
(1) Position of each 15mer peptide in themembrane protein of the yellow fever virus; (2)
molecules of H2d class II IC50 result for the binding assay for H2d class II molecules
(nmol); ⁎values of IC50 below the cutoff of 1000 nmol, suggestive of a possible binder
peptide.
115M. Maciel Jr. et al. / Virology 378 (2008) 105–117contributing to the memory response (Supplemental Fig. 2) (Johansen
et al., 2004; Sun et al., 2004).
The fact that each of the CD4-immunogenic peptides produced
different dose–response curves in the ELISPOT experiments suggests
that the MHC–epitope complex can exhibit distinct avidities for the
CD4+ T cells TCRs (Hesse et al., 2001), a situation that can have
important implications in the choice of epitopes for vaccine develop-
ment. It is important to note that the precise deﬁnition of class II
epitopes is somewhat less clear than class I epitopes. In fact, mouse
MHC class II alleles have been reported to be able to accommodate a
variety of motifs (Kurata and Berzofsky, 1990).
It has been previously reported that the envelope protein and non-
structural protein 3 (NS3) are the main targets for the immune
response against the YF virus (van der Most et al., 2002). Here we have
extended these observations by evaluating the cellular response
against the three structural proteins of the virus. In fact, the number of
immunogenic peptides in the YF envelope protein found in 17DD YF
virus inoculated mice was by far larger than the numbers found in the
capsid and membrane proteins. These results also underscore the
secondary nature of the immune response against the capsid and
membrane proteins of the YF virus when compared to the envelope
protein.
PREDBALB/c is an in silico peptide identiﬁcation tool that uses
quantitativematrices based on binder and non-binder peptide training
datasets to compose equations based on the frequency of amino acids
at speciﬁc positions within the training set of 9mer peptides (Zhang
et al., 2005). In our hands, the software showed to be very sensitive,
predicting almost all positive peptides. However, the ability of the
software to eliminate negative peptideswas lowand, if used before the
ELISPOT assays, it would have avoided the testing of only about one-
quarter of the 120 15mers of the YF envelope protein. In anothersystem, given a list of 41 peptides from the nucleoprotein of the SARS
coronavirus, PREDBALB/c predicted 17 peptides with possible class II
epitopes, and two peptides were found to be positive by in vitro
epitope mapping (Zhao et al., 2007). Taken together, these results
suggest that the PREDBALB/c prediction algorithm is indeed very sensi-
tive, but its speciﬁcity still needs to be improved.
116 M. Maciel Jr. et al. / Virology 378 (2008) 105–117In conclusion, the results of our epitope mapping of the three
structural proteins of the YF virus in BALB/c (H2d) mice suggest that
initial computational screening with high thresholds, followed by
peptide screening of ELISPOT responses in immunized hosts and by
binding assays, may prove to be the most efﬁcient strategy for
epitope discovery and analysis. In addition, the results presented
here have the potential to identify novel correlates for YF protection
in a mouse strain that is commonly used for the validation of YF
vaccines.
Materials and methods
YF vaccine and peptides
The human YF vaccine, composed of attenuated 17DDYF virus, was
a generous gift from Dr. Ricardo Galler (Oswaldo Cruz Foundation, Rio
de Janeiro, Brazil). The vaccine was reconstituted with chilled PBS,
kept in an ice bath, and used for immunization of mice within 4 h of
reconstitution.
A set of 81 peptides of 16 amino acids (16mers), overlapping by 10
amino acids (16×10) and comprising the entire length of the envelope
protein (E) of the YF virus (sequence NCBI entry U17066), was
synthesized by Synpep (California, USA) (Supplemental Table 1). The
purity of this peptide set was stated by the manufacturer to be 70% or
lower, it was not HPLC-puriﬁed, and the amount of peptide per vial
was not provided.
Additional sets of peptides of 15 amino acids (15mers), overlapping
by 11 amino acids (15×11) and comprising the entire length of the
envelope (n=120) (Supplemental Table 2), capsid (C; n=28) (Supple-
mental Table 3), or membrane (M; n=16) (Supplemental Table 4)
proteins of the 17DD YF virus (sequence NCBI entry U17066), were
synthesized by Schafer-N (Copenhagen, Denmark). Peptides of nine
amino acids (9mers), overlapping by 8 amino acids, were synthesized
for regions E57 to E75 (E57–75) and E329 to E343 (E329–343) of the YF
envelope protein (Supplemental Table 5). These peptides were HPLC-
puriﬁed to 80% purity or greater, with the exception of a few peptides
that could not be puriﬁed and were used as crude products. The
identity of each peptide was conﬁrmed bymass spectrometry, and the
amount of puriﬁed peptide was precisely measured. Stock solutions of
all peptides were prepared by dilution in water when possible, or in a
solution of 10 to 100% of DMSO, to a ﬁnal concentration of 20 mg/mL,
and stored at −20 °C. For the ELISPOTassays, the peptides were used at
10, 1, or 0.1 μg/mL as indicated. The maximum DMSO concentration in
the ELISPOT assay was 0.05%.
Animals and immunization protocols
Female BALB/c (H2d) mice, 6 to 8 weeks old (Charles River,
Kingston, NY), were used in the immunization protocols. They were
housed in micro-isolator cages under speciﬁc pathogen-free condi-
tions and manipulated according to Johns Hopkins Institutional
Animal Care and Use Committee (IACUC) protocol number
MO05M336 Three different immunization protocols were used: 1)
Mice were immunized three times subcutaneously (s.c.) at the base of
the tail with 105 or 104 pfu of the human YF vaccine (strain 17DD,
Oswaldo Cruz Foundation, Rio de Janeiro, Brazil) in 50 μL on days 0, 14
and 28. 2) Mice were immunized s.c. with 104 pfu of the vaccine on
days 0 and 21. Memory experiments were performed with animals
immunized s.c. with 104 pfu of the vaccine on day 0, with or without a
boost on day 21, and boosted or not after 4.5 and 9 months. 3) For the
evaluation of epitope avidity/speciﬁcity by ELISPOTassay, BALB/c mice
were immunized once at the base of the tail with 100 μL of an emulsion
v/v of TiterMax® adjuvant (CytRx Corporation, Norcross, GA) contain-
ing 50 μg of an individual 9mer, a pool of 9mers (50 μg of each), or the
15mer E57–71, E63–75 or E329–343 (50 μg) from the YF envelope protein, or
PBS alone. Mice immunized with PBS emulsiﬁed in TiterMax® servedas a negative control. The experiments were performed 15 and 30 days
after the immunization.
ELISPOT assays for enumeration of IFN-γ spot-forming cells (SFC)
Seven to 10 days after the last immunization, the mice were
killed and their spleens were removed. Splenocytes were isolated by
standard methods, and single-cell suspensions, depleted of red
blood cells, were prepared from freshly isolated splenocytes in
culture medium (RPMI 1640 medium supplemented with 10% v/v
fetal bovine serum, 100 U/mL penicillin/streptomycin, 2 mM L-
glutamine, 50 μM 2-mercaptoethanol and 1 M HEPES buffer).
Experiments for evaluation of CD4 and CD8 responses were
performed with CD8- or CD4-depleted cells, following the proce-
dures from Miltenyi Microbeads kits (Miltenyi, Auburn, California,
USA), using LD columns. IFN-γ ELISPOT assays were performed by
using an ELISPOT set from BD-Biosciences Pharmingen (San Diego,
CA), according to the manufacturer's protocol. Initially, the ELISPOT
plates were coated with anti-IFN-γ at 5 μg/mL and incubated at
4 °C/overnight. The plates were blocked with RPMI 1640 containing
10% FCS for 2 h at room temperature, and either total splenocytes
(1×106 cells/well) or CD8- or CD4-depleted cells (0.5–1.0×106 cells/
well) from immunized mice were then added. The cells were
cultured at 37 °C in 5% CO2 with /mL penicillin/streptomycin, 2 mM
L-glutamine), or in the presence of concanavalin A (2.5 μg/mL;
Sigma), 109 pfu/mL of inactivated YF virus as a positive control
(strain 17DD), or individual 15mers or 9mers from the envelope,
capsid, or membrane proteins of the 17DD YF virus at 10 μg/mL,
1 μg/mL, or 0.1 μg/mL, according to the experiment. After 16 h of
culture, the plates were washed and incubated with biotinylated
anti-IFN-γ for 2 h at room temperature, followed by HRP-
conjugated avidin for 1 h at room temperature. Reactions were
developed with AEC substrate (Calbiochem-Novabiochem Corpora-
tion, San Diego, CA). Final enumeration of IFN-γ SFC was performed
using the Immunospot Series 3B Analyzer ELISPOT reader (Cellular
Technologies Ltd, Shaker Heights, OH) with aid of the Immunospot
software version 3.0 (Cellular Technologies Ltd). The data indicate
the number of spot-forming cells (SFC)/106 cells. The results were
considered positive if the number of SFC was above 20 and higher
than the background (culture with medium alone) plus three
standard deviations. The results are presented after subtraction of
the background, which was consistently found to be 10 to 35 spots/
106 cells throughout the experiments.
Binding assays
Binding of peptides to H-2 allomorphs was determined using
quantitative assays based on the inhibition of binding of a radiolabeled
standard peptide to puriﬁed MHC molecules, essentially as described
previously (Sidney et al., 1998). Brieﬂy, 0.1 to 1 nM of a known MHC-
binding radiolabeled peptide was co-incubated at room temperature
with varying amounts of unlabeled test peptides, 1 µM to 1nM H-2
molecules puriﬁed by afﬁnity chromatography, a cocktail of protease
inhibitors and, for class I assays, 1 µM human ß2-microglubulin
(Scripps Laboratories, San Diego, CA). After 2-day incubation, MHC–
peptide complexes were captured on Lumitrac 600 microplates
(Greiner Bio-one, Longwood, FL) coated with monoclonal antibody
28-14-8S, SF1-1.1.1, 34-5-8S, MKD6 or 14.4.4 for Ld, Kd, Dd, I-Ad and
I-Ed, respectively. Bound radioactivity wasmeasured using a TopCount
microscintillation counter (Packard Instrument Co., Meriden, CT).
The concentration of peptide yielding 50% inhibition of the binding of
the radiolabeled probe peptide (IC50) was then calculated. Peptides
were typically tested at six different concentrations covering a
100,000-fold dose range, and in three or more independent assays.
Under the conditions utilized, where [label]b [MHC] and IC50≥ [MHC],
the measured IC50 values are reasonable approximations of the KD
117M. Maciel Jr. et al. / Virology 378 (2008) 105–117values. The peptides used for binding assays were typically ≥80% pure
(Supplemental Tables 2, 3, 4, and 5).
PREDBALB/c epitope prediction software
PREDBALB/c is a freely available, website-based in silico epitope
prediction program (http://antigen.i2r.a-star.edu.sg/predBalbc/) that
scans protein and peptide sequences to look for epitopes that are
capable of being presented in the context of H2d alleles of the BALB/c
mouse strain. It utilizes quantitativematrices that have been validated
using experimentally determined binders and non-binders and also
by in vivo studies using viral proteins to score and rank proteic
sequences of nine amino acids according to their predicted pep-
tide binding to BALB/c major histocompatibility complex (H2d) class I
(H2-Kd, -Dd and -Ld) and class II (I-Ed and I-Ad) molecules (41). This
software analyzes the sequence of each peptide and scores each one
according to the known binding motifs identiﬁed for each allele
throughout a core sequence of nine amino acids within the peptide
sequence. The software supplies a list of all the peptides, ranked from
10 to 0, for each one of the ﬁve alleles of H2d. An additional software
feature allows the use of a threshold, which can be deﬁned by the user.
For the identiﬁcation of possible epitopes, PREDBALB/c was given
the list of all 15mer peptides used in the ELISPOT experiments: 120
peptides from the envelope, 28 peptides from the capsid, and 16
peptides from the membrane protein, according to the published
sequence of the YF virus 17DD (NCBI entry U17066).
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